C:\Program Files\Stnexp\Queries\10642970 (broad).





chain nodes :
11 13 15 16 17 18 19
ring nodes :
1 2 3 4 5 6 7 8 9 20 21 22 23 24 25
chain bonds :
8-11 13-15 13-16 16-17 17-18 18-19 19-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 20-21 20-25 21-22 22-23 23-24 24-25
exact/norm bonds :
4-7 5-9 7-8 8-9 8-11 13-15 13-16 16-17 17-18 18-19 19-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25
isolated ring systems :
containing 1 : 20 :

G1:N,CH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:Atom 13:CLASS
14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom 22:Atom
23:Atom 24:Atom 25:Atom
Generic attributes :
11:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 11: Limited
C,C4-5
N,N1-2

0,00
S,S0

=>
Uploading C:\Program Files\Stnexp\Queries\10642970.str



chain nodes :
11 13 15 16 17 18 19
ring nodes :
1 2 3 4 5 6 7 8 9 20 21 22 23 24 25
chain bonds :
8-11 13-15 13-16 16-17 17-18 18-19 19-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 20-21 20-25 21-22 22-23 23-24
24-25
exact/norm bonds :
4-7 5-9 7-8 8-9 8-11 13-15 13-16 16-17 17-18 18-19 19-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25
isolated ring systems :
containing 1 : 20 :

G1:N,CH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:Atom
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:Atom
21:Atom 22:Atom 23:Atom 24:Atom 25:Atom
Generic attributes :
11:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 11: Limited
C,C4-5
N,N1-2

O,OO
S,SO

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 17:17:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 833 TO ITERATE

100.0% PROCESSED 833 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 14929 TO 18391
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> =>
Uploading C:\Program Files\Stnexp\Queries\10642970 (broad).str



chain nodes :
11 13 15 16 17 18 19
ring nodes :
1 2 3 4 5 6 7 8 9 20 21 22 23 24 25
chain bonds :
8-11 13-15 13-16 16-17 17-18 18-19 19-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 20-21 20-25 21-22 22-23 23-24
24-25
exact/norm bonds :
4-7 5-9 7-8 8-9 8-11 13-15 13-16 16-17 17-18 18-19 19-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25
isolated ring systems :
containing 1 : 20 :

G1:N,CH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:Atom
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:Atom
21:Atom 22:Atom 23:Atom 24:Atom 25:Atom
Generic attributes :
11:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 11: Limited
C,C4-5
N,N1-2

O,OO
S,SO

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s l3 sss sam
SAMPLE SEARCH INITIATED 17:19:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 914 TO ITERATE

100.0% PROCESSED 914 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 16467 TO 20093
PROJECTED ANSWERS: 2 TO 124

L4 2 SEA SSS SAM L3

```
=> s l3 sss ful
FULL SEARCH INITIATED 17:19:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    18153 TO ITERATE

100.0% PROCESSED    18153 ITERATIONS                          40 ANSWERS
SEARCH TIME: 00.00.02

L5            40 SEA SSS FUL L3

=> => s l5
L6             6 L5

=> d l6 1-6 bib,ab,hitstr
```

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:220328 CAPLUS
DN 140:270869
TI Preparation of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase.
IN Ritzeler, Olaf; Jaehne, Gerhard
PA Aventis Pharma Deutschland GmbH, Germany
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA German

Appl. PCT

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022553	A1	20040318	WO 2003-EP8629	20030805
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10237722	A1	20040819	DE 2002-10237722	20020817
	CA 2498559	AA	20040318	CA 2003-2498559	20030805
	EP 1530568	A1	20050518	EP 2003-793685	20030805
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005197353	A1	20050908	US 2003-642970	20030818
PRAI	DE 2002-10237722	A	20020817		
	US 2002-434749P	P	20021219		
	WO 2003-EP8629	W	20030805		

OS MARPAT 140:270869

AB Title compds. [I; X, M = N, CH; R1, R11 = H, F, Cl, Br, iodo, alkyl, cyano, CF3, OR5, NR5R6, COR5, SOxR5, etc.; x = 0-2; R3, R5, R6 = H, alkyl; R2 = (substituted) imidazolyl, imidazolidinyl, indazolyl, isothiazolyl, isoxazolyl, morpholinyl, piperazinyl, pyrazolyl, tetrazolyl, thiadiazolyl, thiazolyl, thiomorpholinyl, triazolyl, etc.; R4 = (substituted) (fused) pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, phthalazinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, etc.], were prepared Thus, 2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-2-diphenylamino-1-hydrazinocarbonylethyl]amide (preparation given) in CH2Cl2 was treated with phosgene followed by stirring for 15 h to give 76% 2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-2-diphenylamino-1-(5-oxo-4,5-dihydro[1,3,4]-oxadiazol-2-yl)ethyl]amide. The latter inhibited IκB kinase with IC50 = 0.050 μM.

IT **669713-30-8P 669713-32-0P 673488-41-0P**
673488-42-1P 673488-43-2P 673488-44-3P
673488-45-4P 673488-46-5P 673488-47-6P
673488-48-7P 673488-49-8P 673488-50-1P
673488-51-2P 673488-52-3P 673488-53-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

RN 669713-30-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(1S)-1-(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)-2-(diphenylamino)ethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 669713-32-0 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, N-[(1S)-2-amino-1-[(diphenylamino)methyl]-2-oxoethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 673488-41-0 CAPLUS

CN 1H-Indole-5-carboxamide, N-[2-amino-1-[[(4-fluorophenyl)-2-pyridinylamino]methyl]-2-oxoethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673488-42-1 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(1S)-1-(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)-2-(phenyl-2-pyridinylamino)ethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 673488-43-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-amino-1-[[(4-fluorophenyl)-2-pyridinylamino]methyl]-2-oxoethyl]-2-(2-amino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 673488-44-3 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-[(4-fluorophenyl)-2-pyridinylamino]-1-(1H-1,2,4-triazol-3-yl)ethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673488-45-4 CAPLUS
CN 1H-Indole-5-carboxamide, N-[(1S)-2-amino-2-oxo-1-[(phenyl-2-thiazolylamino)methyl]ethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 673488-46-5 CAPLUS
CN 1H-Indole-5-carboxamide, N-[(1S)-2-(methoxyamino)-2-oxo-1-[(phenyl-2-pyridinylamino)methyl]ethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 673488-47-6 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-amino-1-[(diphenylamino)methyl]-2-oxoethyl]-2-(2-amino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 673488-48-7 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-amino-2-oxo-1-[(phenyl-2-pyrimidinylamino)methyl]ethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673488-49-8 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-[(2-hydroxyethyl)amino]-2-oxo-1-[(phenyl-2-pyrimidinylamino)methyl]ethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673488-50-1 CAPLUS
CN L-Alanine, N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-indol-5-yl]carbonyl]-3-[phenyl[4-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 673488-51-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-amino-1-[[(4-fluorophenyl)(5-methyl-2-pyrimidinyl)amino]methyl]-2-oxoethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673488-52-3 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[2-amino-2-oxo-1-[(phenyl-2-pyrimidinylamino)methyl]ethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673488-53-4 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[2-amino-2-oxo-1-[(phenyl-2-pyridinylamino)methyl]ethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



IT **669713-39-7P 669713-40-0P 669713-45-5P**
673488-56-7P 673488-58-9P 673488-59-0P
673488-61-4P 673488-62-5P 673488-63-6P
673488-64-7P 673488-67-0P 673488-71-6P
673488-72-7P 673488-73-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)
RN 669713-39-7 CAPLUS
CN L-Alanine, 3-(diphenylamino)-N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-indol-5-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 669713-40-0 CAPLUS
CN L-Alanine, 3-(diphenylamino)-N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-indol-5-yl]carbonyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 669713-45-5 CAPLUS
CN L-Alanine, 3-(diphenylamino)-N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-benzimidazol-5-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 673488-56-7 CAPLUS
CN Alanine, 3-[(4-fluorophenyl)-2-pyridinylamino]-N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-indol-5-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 673488-58-9 CAPLUS
CN L-Alanine, N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-indol-5-yl]carbonyl]-3-(phenyl-2-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 673488-59-0 CAPLUS
CN Alanine, N-[[2-(2-amino-4-pyrimidinyl)-1H-indol-5-yl]carbonyl]-3-[(4-fluorophenyl)-2-pyridinylamino]-, methyl ester (9CI) (CA INDEX NAME)



RN 673488-61-4 CAPLUS
CN L-Alanine, N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-indol-5-yl]carbonyl]-3-(phenyl-2-thiazolylamino)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 673488-62-5 CAPLUS
CN Alanine, N-[[2-(2-amino-4-pyrimidinyl)-1H-indol-5-yl]carbonyl]-3-(diphenylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 673488-63-6 CAPLUS
CN Alanine, N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-indol-5-yl]carbonyl]-3-(phenyl-2-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 673488-64-7 CAPLUS
CN Alanine, N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-indol-5-yl]carbonyl]-3-(phenyl-2-pyrimidinylamino)- (9CI) (CA INDEX NAME)



RN 673488-67-0 CAPLUS
CN L-Alanine, N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-indol-5-yl]carbonyl]-3-[phenyl[4-(trifluoromethyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 673488-71-6 CAPLUS
CN Alanine, 3-[(4-fluorophenyl)(5-methyl-2-pyrimidinyl)amino]-N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-indol-5-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 673488-72-7 CAPLUS
CN Alanine, N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-benzimidazol-5-yl]carbonyl]-3-(phenyl-2-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 673488-73-8 CAPLUS
CN Alanine, N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-benzimidazol-5-yl]carbonyl]-3-(phenyl-2-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:220204 CAPLUS
DN 140:247090
TI Use of substituted indole and benzimidazole IκB kinase inhibitors for the treatment of pain
IN Michaelis, Martin; Ritzeler, Olaf; Jaehne, Gerhard; Rudolphi, Karl; Geisslinger, Gerd; Schaible, Hans-Georg
PA Aventis Pharma Deutschland GmbH, Germany
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022057	A1	20040318	WO 2003-EP8628	20030805
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10237723	A1	20040708	DE 2002-10237723	20020817
	CA 2495455	AA	20040318	CA 2003-2495455	20030805
	EP 1531819	A1	20050525	EP 2003-753349	20030805
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013555	A	20050712	BR 2003-13555	20030805
	US 2004116494	A1	20040617	US 2003-642974	20030818
PRAI	DE 2002-10237723	A	20020817		
	US 2002-434628P	P	20021219		
	WO 2003-EP8628	W	20030805		

OS MARPAT 140:247090
AB The invention discloses the use of indole derivative and benzimidazole derivative
IκB kinase inhibitors that are suitable for producing medicaments for the treatment of pain. Preparation of compds. is described.
IT **669713-30-8P 669713-32-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(indole derivative and benzimidazole derivative IκB kinase inhibitors for the treatment of pain)
RN 669713-30-8 CAPLUS
CN 1H-Indole-5-carboxamide, N-[(1S)-1-(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)-2-(diphenylamino)ethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 669713-32-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[(1S)-2-amino-1-[(diphenylamino)methyl]-2-oxoethyl]-2-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **669713-39-7P 669713-40-0P 669713-45-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(indole derivative and benzimidazole derivative IκB kinase inhibitors for the treatment of pain)
RN 669713-39-7 CAPLUS
CN L-Alanine, 3-(diphenylamino)-N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-indol-5-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 669713-40-0 CAPLUS
CN L-Alanine, 3-(diphenylamino)-N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-indol-5-yl]carbonyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 669713-45-5 CAPLUS
CN L-Alanine, 3-(diphenylamino)-N-[[2-[2-(methylamino)-4-pyrimidinyl]-1H-benzimidazol-5-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:182727 CAPLUS
DN 140:229461
TI Remedy or preventive for kidney disease and method of diagnosing kidney disease
IN Yamada, Masateru; Kurumatani, Hajimu; Sudo, Tetsuo
PA Toray Industries, Inc., Japan
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004017997	A1	20040304	WO 2003-JP9910	20030805
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501719	AA	20040304	CA 2003-2501719	20030805
EP 1550462	A1	20050706	EP 2003-792648	20030805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI JP 2002-229262	A	20020806		
WO 2003-JP9910	W	20030805		

AB It is intended to disclose a novel remedy or preventive for a kidney disease and a method of diagnosing (detecting) a kidney disease. The above-described remedy or preventive for a kidney disease contains a casein kinase 2 inhibitor as the active ingredient. The above-described method of diagnosing a kidney disease comprises measuring the activity or content of casein kinase 2 or the expression dose of a casein kinase 2 gene in a sample separated from a living body.
IT **316833-27-9**
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(remedy or preventive for kidney disease and method of diagnosing kidney disease)
RN 316833-27-9 CAPLUS
CN L-Alanine, 3-(ethylphenylamino)-N-[[2-(4-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:76609 CAPLUS
DN 138:153533
TI Preparation of benzimidazoles as viral polymerase inhibitors
IN Beaulieu, Pierre Louis; Fazal, Gulrez; Goulet, Sylvie; Kukolj, George; Poirier, Martin; Tsantrizos, Youla S.
PA Boehringer Ingelheim (Canada) Ltd., Can.
SO PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003007945	A1	20030130	WO 2002-CA1129	20020718
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2448737	AA	20030130	CA 2002-2448737	20020718
	US 2003236251	A1	20031225	US 2002-198259	20020718
	US 6841566	B2	20050111		
	EP 1411928	A1	20040428	EP 2002-750716	20020718
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005501827	T2	20050120	JP 2003-513553	20020718
PRAI	US 2001-306669P	P	20010720		
	US 2001-338324P	P	20011207		
	WO 2002-CA1129	W	20020718		

OS MARPAT 138:153533
AB Title compds. I [R1 = alkoxy, sulfanyl, carboxy, sulfonamido, amino, carboxamido, etc.; R2 = alkyl, haloalkyl, cycloalkyl, cycloalkenyl, etc.; B, D, X = N, CR5; R5 = H, halo, alkyl, etc.; Z = N, O, NR6; R6 = H, alkyl, cycloalkyl, etc.; R3-4 = H, alkyl, haloalkyl, cycloalkyl, etc.; Y1-2 = O, S; R7 = H, alkyl, cycloalkyl, etc.] are prepared For instance, Et 4-chloro-3-nitrobenzoate (preparation given) is treated with cyclohexylamine (DMSO, 60°, 5 h) and reduced to the corresponding aniline (MeOH, H2-Pd(OH)2/C). This intermediate is treated with 2-pyridinecarboxaldehyde (DMF, oxone) and the resulting adduct saponified (NaOH, HOAc) to give II. Example compds. have IC50 in the hepatitis C RNA-dependent polymerase assay of less than 25 μM.
IT **491584-18-0P 491584-23-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazoles as inhibitors of hepatitis C virus polymerase)
RN 491584-18-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[[(2R)-2-[[[1-cyclohexyl-2-(2-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 491584-23-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[(2R)-2-[[[1-cyclohexyl-2-(1H-pyrrol-2-yl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:319887 CAPLUS
DN 134:326769
TI Preparation of amino acid indolecarboxamides as modulators of NFκB activity.
IN Ritzeler, Olaf; Stilz, Hans Ulrich; Neises, Bernhard; Jaehne, Gerhard; Habermann, Joerg
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001030774	A1	20010503	WO 2000-EP10210	20001017
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19951360	A1	20010503	DE 1999-19951360	19991026
	CA 2389165	AA	20010503	CA 2000-2389165	20001017
	BR 2000015026	A	20020716	BR 2000-15026	20001017
	EP 1261601	A1	20021204	EP 2000-974405	20001017
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	TR 200201144	T2	20030221	TR 2002-200201144	20001017
	EE 200200217	A	20030616	EE 2002-217	20001017
	JP 2003519101	T2	20030617	JP 2001-533128	20001017
	NZ 518587	A	20040625	NZ 2000-518587	20001017
	AU 781553	B2	20050526	AU 2001-12728	20001017
	RU 2255087	C2	20050627	RU 2002-113651	20001017
	NO 2002001808	A	20020417	NO 2002-1808	20020417
	ZA 2002003204	A	20021023	ZA 2002-3204	20020423
	US 2003119820	A1	20030626	US 2002-263691	20021004
	HK 1049671	A1	20050401	HK 2003-101851	20030314
	US 2004209868	A1	20041021	US 2004-842427	20040511
PRAI	DE 1999-19951360	A	19991026		
	WO 2000-EP10210	W	20001017		
	US 2000-695412	B1	20001025		
	US 2002-263691	A1	20021004		

OS MARPAT 134:326769
AB Title compds. [I; 1 of R1-R4 = DNR7CHR8Z; the remainder of R1-R4 = H, halo, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, etc.; D = CO, SO, SO2; R7 = H, alkyl; R8 = R9, amino acid residue; R9 = halo, cyano, CF3, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, etc.; Z = (substituted) aryl, heteroaryl, heterocyclyl, etc.; R7R8, R8Z = atoms to form a specified ring; R5 = H, OH, O; R6 = (substituted) aryl, heteroaryl, heterocyclyl], were prepared Thus, 2,3-diphenyl-1H-indol-5-carboxylic acid in DMF was treated successively with L-homophenylalaninamide hydrochloride, TOTU, and diisopropylamine followed by 6 h stirring to give 2,3-diphenyl-1H-indol-5-carboxylic acid (1-carbamoyl-3-phenylpropyl)amide. Tested I inhibited IκB kinase with IC50 = 0.050-32 μM.

IT **336857-97-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid indolecarboxamides as modulators of NFκB activity)
RN 336857-97-7 CAPLUS
CN 1H-Indole-5-carboxamide, N-[(1S)-2-amino-1-[(ethylphenylamino)methyl]-2-oxoethyl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **336858-04-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid indolecarboxamides as modulators of NFκB activity)
RN 336858-04-9 CAPLUS
CN L-Alanine, 3-(ethylphenylamino)-N-[[2-(4-pyridinyl)-1H-indol-5-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:12443 CAPLUS
DN 134:86539
TI Preparation of benzimidazolecarboxylic acid amino acid amides as IκB kinase inhibitors.
IN Ritzeler, Olaf; Stilz, Hans Ulrich; Neises, Bernhard; Bock, William Jerome, Jr.; Walser, Armin; Flynn, Gary A.
PA Aventis Pharma Deutschland GmbH, Germany
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001000610	A1	20010104	WO 2000-EP5340	20000609
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19928424	A1	20001228	DE 1999-19928424	19990623
	DE 10006297	A1	20010816	DE 2000-10006297	20000212
	CA 2377085	AA	20010104	CA 2000-2377085	20000609
	BR 2000012450	A	20020402	BR 2000-12450	20000609
	EP 1194425	A1	20020410	EP 2000-938780	20000609
	EP 1194425	B1	20050810		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003503400	T2	20030128	JP 2001-507019	20000609
	EE 200100619	A	20030217	EE 2001-619	20000609
	NZ 516348	A	20030630	NZ 2000-516348	20000609
	AU 769350	B2	20040122	AU 2000-54042	20000609
	NO 2001006154	A	20020219	NO 2001-6154	20011217
	HK 1047582	A1	20050304	HK 2002-108645	20021129
PRAI	DE 1999-19928424	A	19990623		
	DE 2000-10006297	A	20000212		
	WO 2000-EP5340	W	20000609		

OS MARPAT 134:86539
AB Title compds. [I; 1 of R1-R4 = DNR8CHR9Z; D = CO, SO, SO2; R8 = H, alkyl; R9 = amino acid residue, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, etc.; Z = (substituted) aryl, heteroaryl, heterocyclyl, etc.; the remainder of R1-R4 = H, halo, alkyl, (substituted) heteroaryl, heterocyclyl, alkyl, cyano, aralkoxy, alkoxy, etc.; R5 = H, OH, O; R6 = (substituted) aryl, Ph, heteroaryl, heterocyclyl], were prepared Thus, 2-pyrid-4-ylbenzimidazol-4-carboxylic acid (preparation given), H-Leu-OMe, TOTU, and (Me2CH)2EtN were stirred in MeCN to give 98% 2-pyrid-4-ylbenzimidazol-4-carbonylleucine Me ester. I inhibited IκB kinase with IC50 = 0.07-72 μM.
IT **316832-70-9P 316832-75-4P 316832-76-5P**
316833-28-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazolecarboxylic acid amino acid amides as IκB kinase inhibitors)

RN 316832-70-9 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, N-[(1S)-2-amino-2-oxo-1-[(phenylamino)methyl]ethyl]-2-(4-pyridinyl)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 316832-69-6
CMF C22 H20 N6 O2

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 316832-75-4 CAPLUS

CN L-Alanine, 3-(phenylamino)-N-[[2-(4-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316832-76-5 CAPLUS

CN L-Alanine, 3-(phenylamino)-N-[[2-(4-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 316832-75-4
CMF C22 H19 N5 O3

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 316833-28-0 CAPLUS
CN L-Alanine, 3-(ethylphenylamino)-N-[[2-(4-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 316833-27-9
CMF C24 H23 N5 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **316833-39-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzimidazolecarboxylic acid amino acid amides as IκB kinase inhibitors)
RN 316833-39-3 CAPLUS
CN L-Alanine, 3-(ethylphenylamino)-N-[[2-(4-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> => d his

     (FILE 'HOME' ENTERED AT 17:17:07 ON 14 SEP 2005)

     FILE 'REGISTRY' ENTERED AT 17:17:14 ON 14 SEP 2005
L1             STRUCTURE UPLOADED
L2           2 S L1 SSS SAM
L3             STRUCTURE UPLOADED
L4           2 S L3 SSS SAM
L5          40 S L3 SSS FUL

     FILE 'CAPLUS' ENTERED AT 17:20:05 ON 14 SEP 2005
L6           6 S L5

     FILE 'CAOLD' ENTERED AT 17:20:32 ON 14 SEP 2005

=> s l5
L7           0 L5

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.43     193.78

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -4.38

STN INTERNATIONAL LOGOFF AT 17:20:43 ON 14 SEP 2005
```